From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

2014 ◽  
Vol 70 (1) ◽  
pp. 168-177 ◽  
Author(s):  
Jeremy Hugh ◽  
Abby S. Van Voorhees ◽  
Rajiv I. Nijhawan ◽  
Jerry Bagel ◽  
Mark Lebwohl ◽  
...  
Open Heart ◽  
2019 ◽  
Vol 6 (1) ◽  
pp. e000943 ◽  
Author(s):  
Leopold Ndemnge Aminde ◽  
Linda J Cobiac ◽  
J Lennert Veerman

ObjectiveTo assess the potential impact of reduction in salt intake on the burden of cardiovascular disease (CVD) and premature mortality in Cameroon.MethodsUsing a multicohort proportional multistate life table model with Markov process, we modelled the impact of WHO’s recommended 30% relative reduction in population-wide sodium intake on the CVD burden for Cameroonian adults alive in 2016. Deterministic and probabilistic sensitivity analyses were conducted and used to quantify uncertainty.ResultsOver the lifetime, incidence is predicted to decrease by 5.2% (95% uncertainty interval (UI) 4.6 to 5.7) for ischaemic heart disease (IHD), 6.6% (95% UI 5.9 to 7.4) for haemorrhagic strokes, 4.8% (95% UI 4.2 to 5.4) for ischaemic strokes and 12.9% (95% UI 12.4 to 13.5) for hypertensive heart disease (HHD). Mortality over the lifetime is projected to reduce by 5.1% (95% UI 4.5 to 5.6) for IHD, by 6.9% (95% UI 6.1 to 7.7) for haemorrhagic stroke, by 4.5% (95% UI 4.0 to 5.1) for ischaemic stroke and by 13.3% (95% UI 12.9 to 13.7) for HHD. About 776 400 (95% UI 712 600 to 841 200) health-adjusted life years could be gained, and life expectancy might increase by 0.23 years and 0.20 years for men and women, respectively. A projected 16.8% change (reduction) between 2016 and 2030 in probability of premature mortality due to CVD would occur if population salt reduction recommended by WHO is attained.ConclusionAchieving the 30% reduction in sodium intake recommended by WHO could considerably decrease the burden of CVD. Targeting blood pressure via decreasing population salt intake could translate in significant reductions in premature CVD mortality in Cameroon by 2030.


2018 ◽  
Vol 3 (2) ◽  
pp. 65-70 ◽  
Author(s):  
Monique Kamaria ◽  
Wilson Liao ◽  
J. Y. Koo

The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29.9 weeks in Psoriasis Area and Severity Index [PASI] 75 responders), followed by ustekinumab (22 weeks), infliximab (19.5 weeks), adalimumab (18 weeks), etanercept (12.1 weeks in PASI 50 responders), and lastly efalizumab (9.6 weeks). Rebound was reported commonly for efalizumab (14%) and extremely rarely for etanercept (0.002%).


2019 ◽  
Vol 5 (1) ◽  
pp. 28-31
Author(s):  
Amy Blake ◽  
Clinton Enos ◽  
April W. Armstrong ◽  
Amit Garg ◽  
Alice Gottlieb ◽  
...  

Background: There is limited literature on the occurrence and management of psoriasis involving the ear. Objective: To better understand psoriasis of the ear and current approaches for management. Methods: The Medical Board of the National Psoriasis Foundation was surveyed on the frequency and presentation of psoriasis of the ear, the types of examinations performed, and the rationale for choice of treatment. Results: In this survey, the observed frequency of ear psoriasis was wide (10%-70%). The scalp was the most common concurrent site of extra-auricular psoriasis. Inspection of the ear was commonly reported; however, 75% of respondents report not inspecting the canal. Topical corticosteroids were the most commonly used treatment. Systemic and biologic therapies are infrequently used. Limitations: This study is limited by the sample size of respondents. Not every question of the survey was answered by all those surveyed. Conclusions: Results from our survey suggest that the evaluation of psoriasis of the ear is often not complete. Inspection of the ear, including the canal, is recommended, especially if the scalp is involved. Routine inspection of the ear is recommended both to evaluate treatment response and for potential adverse side effects. In the setting of persistent ear disease, collaboration between dermatologists and otolaryngologists is encouraged.


2012 ◽  
Vol 7 (4) ◽  
pp. 443-453 ◽  
Author(s):  
Marzieh Hosseini Araghi ◽  
G Neil Thomas ◽  
Shahrad Taheri

2010 ◽  
Vol 62 (4) ◽  
pp. 655-662 ◽  
Author(s):  
Misha Rosenbach ◽  
Sylvia Hsu ◽  
Neil J. Korman ◽  
Mark G. Lebwohl ◽  
Melodie Young ◽  
...  

2016 ◽  
Vol 68 (8) ◽  
pp. 818-833 ◽  
Author(s):  
Yanping Li ◽  
Dong D. Wang ◽  
Sylvia H. Ley ◽  
Annie Green Howard ◽  
Yuna He ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document